Towards Better Choices in Care
Author:
Werner Gijsbert D. A.,van Riel Arthur,Gijsberts Mérove I. L.,de Visser Marianne
Abstract
AbstractIn the previous chapter we noted that the way choices are made in health and social care in the Netherlands, and thus the results of those choices, is not always ideal. Greater health gains could probably be achieved by deploying people and resources more effectively than is currently the case. The quality and accessibility of care could also be better assured, especially for vulnerable groups. Where limits are imposed upon the growth of care, this is not always done in the most prudent way. We also discussed five impediments to good choices and distribution in care.
Publisher
Springer Nature Switzerland
Reference41 articles.
1. Angelis, A., Lange, A., & Kanavos, P. (2018). Using health technology assessment to assess the value of new medicines: Results of a systematic review and expert consultation across eight European countries. European Journal of Health Economics, 19(1), 123–152. 2. Baltussen, R., Bijlmaker, L., Van der Burg, S., Van Dijk, W., Groenewoud, S., Jansen, M., Tummers, M., Helderman, K., Boer, B., Van Exel, J., & Zwaap, J. (2018). Draagvlak voor lastige keuzes. Eindrapport van het Burgerforum ‘Keuzes in de zorg’. RadboudUMC. 3. Bertens, R. M., & Palamar, J. (2021). Het Nederlandse zorgbeleid in historisch perspectief, 1941–2017. WRR Working Paper 45. The Netherlands Scientific Council for Government Policy (WRR). 4. Bijlmakers, L., Jansen, M., Boer, B., Van Dijk, W., Groenewoud, S., Zwaap, J., Helderman, J. K., Van Exel, J., & Baltussen, R. (2020). Increasing the legitimacy of tough choices in healthcare reimbursement: Approach and results of a citizen forum in The Netherlands. Value in Health, 23(1), 32–38. 5. Böhm, K., Landwehr, C., & Steiner, N. (2014). What explains ‘generosity’ in the public financing of high-tech drugs? An empirical investigation of 25 OECD countries and 11 controversial drugs. Journal of European Social Policy, 24(1), 39–55.
|
|